Allos' Folotyn falls at EU regulator: casts doubt over future US sales
This article was originally published in Scrip
On 19 January 2012, the Committee for Medicinal Products for Human Use (CHMP) recommended that the European Medicines Agency refuse a marketing authorisation for Allos Therapeutics' folate analogue, Folotyn (pralatrexate), a designated orphan product for treating peripheral T-cell lymphoma (PTCL).
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.